WangJR, ZafereoME, DaduR, et al.Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid2019;29(8):1036‐1043; doi: 10.1089/thy.2019.0133.
2.
ZhaoX, WangJR, DaduR, et al.Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: A single-center retrospective cohort study. Thyroid2023;33(4):484‐491; doi: 10.1089/thy.2022.0504.
3.
BauzonJ, Ponce de Leon-BallesterosG, LincangoE, et al.Neoadjuvant therapy with multikinase inhibitors for locally advanced differentiated thyroid cancer: A systematic review. Thyroid2025;35(10):1108‐1119; doi: 10.1177/10507256251367286.
4.
BusaidyNL, KondaB, WeiL, et al.Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial. Thyroid2022;32(10):1184‐1192; doi: 10.1089/thy.2022.0115.
5.
BroseMS, CabanillasME, CohenEEW, et al.Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: A non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol2016;17(9):1272‐1282; doi: 10.1016/S1470-2045(16)30166-8.
6.
Late breaking oral abstracts. Thyroid2025;35(S1):e106‐e143.
7.
WirthLJ, ShermanE, RobinsonB, et al.Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med2020;383(9):825‐835; doi: 10.1056/NEJMoa2005651.
8.
BroseMS, NuttingCM, JarzabB, et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet2014;384(9940):319‐328; doi: 10.1016/S0140-6736(14)60421-9.
9.
SchlumbergerM, TaharaM, WirthLJ, et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med.2015;372(7):621‐630; doi: 10.1056/NEJMoa1406470.
